Farmácia/Notícias da Indústria
CDC alerta que as vacinas contra Covid-19 podem não proteger pessoas imunocomprometidas – “O CDC está investigando pesquisas em andamento sobre a possibilidade de pacientes imunocomprometidos terem benefício com uma dose adicional.”
19 Jul, 2021 | 09:59hCDC warns Covid-19 vaccines might not protect people who are immunocompromised – CNN
M-A | Relação risco/benefício das estatinas na prevenção primária de doença cardiovascular é geralmente favorável.
19 Jul, 2021 | 09:51hComunicado de imprensa: New study suggests benefit-to-harm balance of statins for healthy adults ‘generally favorable’ – BMJ
Comentário no Twitter
Statins are associated with a small increased risk of side effects in patients without a history of heart disease, but these effects are mild compared with the potential benefits of treatment in preventing major cardiovascular events, say researchers https://t.co/Yvn7Ojtx2F
— The BMJ (@bmj_latest) July 17, 2021
Por que um grande estudo sobre ivermectina para Covid-19 foi excluído da revista onde foi publicado?
16 Jul, 2021 | 10:01hWhy Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review
Ver também: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian E Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog E Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd
Comentário no Twitter (fio – clique para saber mais)
So, one of the biggest studies to date on ivermectin for COVID-19 has issues significant enough that, if not fraud, are so serious that it invalidates the study without further explanation
I promised a thread
Here we go 1/n https://t.co/L9QOChmGtA
— Health Nerd (@GidMK) July 16, 2021
Vacinação heteróloga com doses da Oxford–AstraZeneca e da Moderna induz aumento nos níveis de anticorpos neutralizantes em comparação a 2 doses da vacina da Oxford–AstraZeneca.
16 Jul, 2021 | 09:58hHeterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine
Relacionado: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. E Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. E RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Comentário no Twitter
Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered either ChAdOx1 nCoV-19 or mRNA-1273 9 to 12 weeks later. Levels of S-specific and RBD-specific IgG increased by a factor of 5 after ChAdOx1 nCoV-19 and by a factor of 115 to 125 after mRNA-1273.
— NEJM (@NEJM) July 14, 2021
Vacinação heteróloga com doses da Oxford–AstraZeneca e da BioNTech/Pfizer induz aumento nos níveis de anticorpos neutralizantes em comparação a 2 doses da vacina da Oxford–AstraZeneca.
16 Jul, 2021 | 09:57hHeterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine
Relacionado: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. E Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. E RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Comentário no Twitter
Mix and match vaccines?
2 doses AZ vs AZ and then Pfizer:
"BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants" https://t.co/53J2erWVMy pic.twitter.com/aEmqMlhEar— Eric Topol (@EricTopol) July 14, 2021
Revisão | Sedação na unidade de terapia intensiva.
16 Jul, 2021 | 09:42hSedation in the Intensive Care Unit – Current Anesthesiology Reports
Estudo randomizado | Banlanivimabe com etesevimabe reduz a mortalidade e a hospitalização em pacientes ambulatoriais com início de Covid-19 (até 3 dias de um teste positivo) que estão sob risco de piora clínica (p.ex., idosos, obesos, diabéticos, imunocomprometidos, portadores de doença cardiovascular).
15 Jul, 2021 | 10:41hBamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine
Tramadol: para onde vamos a partir de agora? – “O tramadol e sua imprevisibilidade, seus inigualáveis danos potenciais e sua falta de vantagem sobre outros opioides ou anti-inflamatórios não hormonais (AINH) são agora reconhecidos.”
15 Jul, 2021 | 10:31hEstudo randomizado | Ranibizumabe intravítreo vs. aflibercepte vs. bevacizumabe para edema macular decorrente de oclusão da veia central da retina.
15 Jul, 2021 | 10:27hEstudo randomizado | Lopinavir-ritonavir e hidroxicloroquina pioraram os desfechos em pacientes criticamente doentes com COVID-19.
14 Jul, 2021 | 11:49h
Comentário no Twitter (fio – clique para saber mais)
Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy
— remap-cap (@remap_cap) July 13, 2021